United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the business’s stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $450.86, for a total value of $1,803,440.00. Following the completion of the transaction, the chief executive officer directly owned 130 shares of the company’s stock, valued at approximately $58,611.80. This trade represents a 96.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Down 1.7%

UTHR stock opened at $448.93 on Thursday. The company has a market cap of $20.25 billion, a PE ratio of 17.52, a price-to-earnings-growth ratio of 6.96 and a beta of 0.66. The business has a 50-day simple moving average of $365.94 and a 200 day simple moving average of $321.87. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $459.48.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm’s revenue for the quarter was up 11.7% compared to the same quarter last year. During the same period last year, the firm earned $5.85 EPS. On average, analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wedmont Private Capital bought a new stake in shares of United Therapeutics during the third quarter worth about $725,000. Quantum Financial Advisors LLC bought a new stake in shares of United Therapeutics during the third quarter worth about $217,000. GAMMA Investing LLC grew its holdings in shares of United Therapeutics by 11.1% during the third quarter. GAMMA Investing LLC now owns 1,147 shares of the biotechnology company’s stock worth $481,000 after purchasing an additional 115 shares during the last quarter. Corient Private Wealth LLC grew its holdings in shares of United Therapeutics by 3.2% during the second quarter. Corient Private Wealth LLC now owns 17,800 shares of the biotechnology company’s stock worth $5,115,000 after purchasing an additional 544 shares during the last quarter. Finally, Texas Permanent School Fund Corp boosted its holdings in United Therapeutics by 7.2% in the second quarter. Texas Permanent School Fund Corp now owns 51,394 shares of the biotechnology company’s stock valued at $14,768,000 after acquiring an additional 3,440 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on UTHR shares. Cantor Fitzgerald boosted their target price on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. Wells Fargo & Company boosted their target price on United Therapeutics from $295.00 to $414.00 and gave the stock an “equal weight” rating in a research note on Wednesday, September 3rd. Morgan Stanley lowered their target price on United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating for the company in a research note on Thursday, July 10th. HC Wainwright boosted their target price on United Therapeutics from $400.00 to $500.00 and gave the stock a “buy” rating in a research note on Friday, September 5th. Finally, Bank of America boosted their target price on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. Ten analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $449.57.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.